Last reviewed · How we verify
DU-176b (edoxaban)
Edoxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.
Edoxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism treatment and prevention, Acute coronary syndrome.
At a glance
| Generic name | DU-176b (edoxaban) |
|---|---|
| Sponsor | Daiichi Sankyo Co., Ltd. |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Edoxaban selectively inhibits Factor Xa, a serine protease critical in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa activity, it prevents the generation of thrombin and subsequent fibrin clot formation, reducing thrombotic events. As an oral anticoagulant, it provides systemic anticoagulation without requiring monitoring or dose adjustment in most patients.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis and pulmonary embolism treatment and prevention
- Acute coronary syndrome
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Nausea
- Rash
Key clinical trials
- Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE
- Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease (PHASE3)
- Study of DU-176b Aged 80 Years or Older (PHASE3)
- Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) (PHASE3)
- Cancer Venous Thromboembolism (VTE) (PHASE3)
- A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (PHASE3)
- Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (PHASE3)
- Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |